McMaster University and Promation have signed a Memorandum of Understanding (MoU) to work together to bring a new medical isotope technology developed at McMaster to the marketplace.

This partnership brings together two groups of experts with complementary skills. At the center of this collaboration is a new technology for producing lutetium-177 (Lu-177), an increasingly sought-after medical isotope. Clinical trials have shown that Lu-177-based drugs have tremendous potential for treating a wide range of cancers. McMaster is widely recognized for its expertise in developing and commercializing medical isotope-based technologies, and promation is a Canadian leader in the design and building of best-in-class automation solutions, with an expert team capable of developing specialty tooling and equipment that meets the stringent needs of the nuclear energy and medical isotope sectors.

To read more please visit:

New partnership advances medical isotope technology | Canadian Nuclear Isotope Council (canadianisotopes.ca)

Source: CANDIAN NUCLEAR ISOTOPE COUNCIL